Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells

Imatinib, a breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myelogenous leukemia (CML). However, development of multidrug resistance (MDR) limits the use of imatinib. In the present study, we aimed to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xing-Xiang, Tiwari, Amit K., Wu, Hsiang-Chun, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777469/
https://www.ncbi.nlm.nih.gov/pubmed/22098951
http://dx.doi.org/10.5732/cjc.011.10327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777469/
https://www.ncbi.nlm.nih.gov/pubmed/22098951
http://dx.doi.org/10.5732/cjc.011.10327

Ejemplares similares